RaySearch Laboratories AB (publ) Interim Report January 1 - March 31 2008

RaySearch Laboratories AB (publ) Interim Report January 1 - March 31 2008

JANUARY 1 - MARCH 31 2008 
• Net sales for the period amounted to SEK 15.6 M (16.1) 

• Profit after tax was SEK 3.1 M (5.2) 

• Earnings per share amounted to SEK 0.27 (0.46) 

• Operating profit amounted to SEK 3.6 M (7.1) 

• Cash flow from operating activities amounted to SEK 1.2 M (13.4)

• The first revenues were recorded for COMPASS® and the agreement with IBA
Dosimetry was expanded

AFTER THE END OF THE REPORTING PERIOD
• Release of first product from Varian collaboration postponed

• Negotiations in final stages with Philips regarding development of a new
product for the new revolutionary treatment method VMAT

• As a result of the market driven prioritization of VMAT, the first product
release within adaptive radiation therapy will been delayed

”We are currently finalizing the negotiations with Philips regarding a new
product for VMAT which is a new exciting area with very large potential.
However, this also means that the first product release from the collaboration
with Philips regarding adaptive radiotherapy will be postponed,” says Johan Löf,
CEO of RaySearch.

“The COMPASS® collaboration with IBA Dosimetry has now started to generate
revenues. We have also expanded the COMPASS® collaboration with a new product
that, together with the new Philips product, further strengthens our broad
growth platform.”

”The first product release from the Varian collaboration has been postponed
until next year. The delay is not due to any technical reasons” concludes Johan
Löf.

FOR FURTHER INFORMATION, CONTACT:

Johan Löf, President and CEO
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

RaySearch Laboratories AB (publ)
Corp. Reg. No. 556322-6157
Sveavägen 25
SE-111 34 Stockholm 

ABOUT RAYSEARCH

RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have
been released to date and RaySearch's software is used at over 1,300 clinics in
more than 30 countries. In addition, existing license agreements cover more than
15 other products that are scheduled to be launched in the coming years.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the SmallCap segment on the OMX Nordic
Exchange Stockholm. 

For more information about RaySearch, visit www.raysearchlabs.com.